Cytosorbents Corporation (CTSO)
NASDAQ: CTSO
· Real-Time Price · USD
1.18
-0.04 (-3.28%)
At close: Jun 17, 2025, 12:04 PM
Cytosorbents Revenue Breakdown
| Period Ending | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
| Grant income Revenue | 5.26M | 787.2K |
| Grant income Revenue Growth | +568.75% | n/a |
| Other sales Revenue | 69.69K | n/a |
| Other sales Revenue Growth | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| All Other Countries Revenue | 22.39M | 18.05M | 15.82M | 17.41M |
| All Other Countries Revenue Growth | +24.04% | +14.08% | -9.12% | n/a |
| Germany Revenue | 13.05M | 12.96M | n/a | n/a |
| Germany Revenue Growth | +0.66% | n/a | n/a | n/a |
| United States Revenue | 150.61K | 5.26M | 968.95K | 1.69M |
| United States Revenue Growth | -97.14% | +443.31% | -42.66% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 8.43M | 9.52M | 7.83M | 8.4M | 8.57M | 9.24M | 9.21M | 8.91M | 9.13M | 8.71M | 8.73M | 9.12M | 9.96M | 11.08M | 8.44M | 10.54M | 7.71M | 9.38M | 7.86M | 7.44M | 6.84M | 7.21M | 6.84M | 5.1M | 5.32M | 7.16M | 4.46M | 6.58M | 4.68M | 4.77M | 3.92M | 3.93M | 2.95M | 3.51M | 2.42M | 2.63M | 2.23M | 2.37M | 1.99M | 1.92M | 2.18M |
| Selling, General, and Administrative Revenue Growth | -11.42% | +21.62% | -6.84% | -1.93% | -7.30% | +0.37% | +3.36% | -2.45% | +4.84% | -0.27% | -4.20% | -8.47% | -10.11% | +31.30% | -19.91% | +36.69% | -17.78% | +19.27% | +5.71% | +8.79% | -5.16% | +5.36% | +34.16% | -4.15% | -25.69% | +60.62% | -32.29% | +40.70% | -1.85% | +21.61% | -0.23% | +33.29% | -16.02% | +45.00% | -7.81% | +17.98% | -6.04% | +19.05% | +3.38% | -11.70% | n/a |
| Research and Development Revenue | 1.66M | 1.3M | 1.85M | 1.52M | 2.25M | 4.1M | 3.75M | 3.67M | 4.21M | 3.4M | 3.29M | 4.18M | 4.24M | 6.14M | 4.26M | 3.7M | 2.28M | 2.69M | 1.75M | 2.41M | 1.97M | 3.56M | 3.19M | 2.93M | 2.42M | 2.42M | 1.94M | 1.58M | 1.78M | 2.42M | 537.95K | 487.61K | 469.55K | 1.66M | 1.17M | 1.09M | 856.12K | 1.25M | 866.33K | 801.66K | 951.03K |
| Research and Development Revenue Growth | +28.22% | -29.93% | +21.78% | -32.38% | -45.12% | +9.26% | +2.18% | -12.93% | +23.87% | +3.40% | -21.35% | -1.41% | -30.86% | +43.99% | +15.22% | +62.09% | -15.04% | +53.14% | -27.10% | +22.44% | -44.77% | +11.71% | +8.70% | +21.12% | -0.21% | +24.76% | +23.29% | -11.46% | -26.48% | +350.04% | +10.32% | +3.85% | -71.77% | +41.89% | +7.33% | +27.55% | -31.62% | +44.52% | +8.07% | -15.71% | n/a |